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Although most evident in the skin, the process of scarring, or fibrosis, occurs in all major organs because of impaired epithelial
self-renewal. No current therapy exists for Idiopathic pulmonary fibrosis. The major profibrotic factor is TGF-β1 and developing
inhibitors is an area of active research. Recently, IGFBP-5 has also been identified as a profibrotic factor, and studies suggest
that, while both TGF-β1 and IGFBP-5 activate mesenchymal cells to increase collagen and fibronectin production, their eects
on epithelial cells are distinct. TGF-β1 induces cell death and/or EMT in the epithelial cells, exacerbating the disruption of tissue
architecture. In contrast, IGFBP-5 induces epithelial cell spreading over collagen or fibronectin matrices, increases secretion of
laminin, the epithelial basement membrane, and enhances the survival of epithelial cells in nutrient-poor conditions, as exists in
scar tissue. Thus, IGFBP-5 may enhance repair and may be an important target for antifibrotic therapies.
1. Introduction
Idiopathic Pulmonary fibrosis (IPF) is a nonneoplastic
chronic lung syndrome that is characterized by aberrant
accumulation of fibroblasts/myofibroblasts and progressive
abnormal remodelling of lung parenchyma, with subsequent
scarring and disruption of its structure and function. It
belongs to a broad category of 200 disorders called diuse
pulmonary lung diseases (DPLDs) or simply interstitial lung
diseases (ILDs). This is further classified into a subgroup
known as idiopathic interstitial pneumonia (IIP), where IPF
is one of the seven diseases, being the most prevalent and
pernicious disorder. It is subclassified with a pathological
condition known as usual interstitial pneumonia (UIP).
Major symptoms include chronic dyspnea (shortness of
breath) induced by 6-minute walk test, persistent dry cough,
reduced lung volume, and impaired gas exchange. Constitu-
tional symptoms include weight loss, fatigue, finger clubbing,
and general malaise [1]. IPF has a poor prognosis and is five
times more prevalent than cystic fibrosis and amyotrophic
lateral sclerosis, with no FDA approved treatments. Despite
considerable recent progress, current treatment regimens
are largely unpromising with a median survival rate of
less than three years from the date of diagnosis [2]. The
precise mechanisms involved in the pathogenesis of IPF have
not been completely understood. Here, in this paper, we
attempt to highlight the pathology of pulmonary fibrogenesis
from its history, possible cellular and molecular mechanisms,
and draw comparisons between the major profibrotic factor
TGF-β1 and a more recently described player, IGFBP-5.
2. IPF Incidence and Pathophysiology
IPF is usually a disease of the elderly and occurs after five
decades of life, with the probability of incidence markedly
increasing thereafter. The onset of disease is slow but
with age and time, the symptoms increase. There are five
million suerers, with increasing world-wide incidence, that
are aected by IPF [3]. The number of aected patients
has doubled in the past decade [4] and inevitably will
increase in developed countries due to increasing age of the
population. The disease is slightly more prevalent in men [5]
and strongly associated with cigarette smoking [6]. Recent
statistics of large United States and UK population-based
studies indicated a significant increase in mortality [7, 8].
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Annually, 40,000 and 4,000 new cases were diagnosed each
year in US and UK, respectively.
Pulmonary fibrosis can also occur due to a variety of
stimuli ranging from life style habits such as cigarette smok-
ing [6], occupational exposure to polluted environments,
notably asbestos or silica [9], induced by pharmacological
agents [10], radiation exposure [11], and genetic predisposi-
tion [5], or associated with other autoimmune abnormalities
such as collagen vascular diseases [12, 13].
3. Epithelial Cell Injury and IPF
The complex signalling mechanisms of pulmonary epithelial
cell injury in response to fibrosis are of considerable research
interest. As intact alveolar epithelium is critical for main-
taining lung homeostasis, initiation of repair mechanisms
following the insult and injury, without compromising
its structure and function, is of great importance. Our
understanding of the relationship between injury of epithelia
and development of IPF has increased dramatically in recent
years. Current hypotheses suggest that microrepetitive injury
to pulmonary epithelial cells results in ineective repair
with subsequent fibrogenesis. As previously mentioned,
the sources of recurrent injury could be wide ranging
and include toxic or drug-induced insults, autoimmune
disease, traumatic or hypoxic injuries, and bacterial or viral
infections. Recently, a high occurrence of Epstein Barr Virus
(EBV) expressing latent membrane protein (LMB-1) has
been reported in IPF patients with synergizing eects with
TGF-β-induced EMT in lung epithelial cells [14]. Observa-
tions suggest that the release of soluble growth factors after
injury including chemokines, eicosanoids, and interleukins
has also shown to be involved in the resolution of epithelial
repair processes. However, there may be compromise with
respect to structure and functional organisation with varying
degree of injuries.
4. The Role of Fibroblasts/Myofibroblasts
in IPF
Eective therapies to prevent tissue fibrosis require a com-
plete understanding of the mechanisms involved in the
development of the disease, and one mechanism of particular
interest is fibroblast development. Resident fibroblasts and
resident activated fibroblasts (myofibroblasts) are critical cell
types for the process of wound healing and also for the for-
mation of fibrotic lesions in the pathogenesis of lung fibrosis.
Fibroblasts express receptors for a number of cytokines
including PDGF [15], TGF-β1 [16], and TNF-α [16]. These
cytokines and others may mediate their recruitment and
activation during injury. In addition to their involvement
in skin wound healing [17–19], myofibroblasts are most
commonly identified and well characterized in idiopathic
pulmonary fibrosis [20]. Myofibroblasts are mesenchymal
cells with characteristics of both fibroblasts and smooth
muscle cells [21]. The origin of myofibroblasts is still under
debate. However, persistence of fibroblasts/myofibroblasts at
the site of injury and extracellular matrix (ECM) are critical
for fibrotic lesion formation in IPF [22]. Thus, understand-
ing the mechanism of the gradual decrease of myofibroblasts,
as occurs in normal wound healing, should be important for
the resolution of pulmonary fibrosis.
5. Epithelial to Mesenchymal Transition
EMT is a prominent manifestation of cell plasticity observed
in three distinct cellular processes: embryonic develop-
ment, metastasis, and fibrosis. Here, as per the context,
determination of the cellular source of myofibroblasts is
crucial in understanding the pathogenesis of tissue fibrosis.
Myofibroblasts appear to have at least three possible origins.
Alveolar epithelial damage with consequent EMT, activation
of fibroblasts, and circulating fibrocytes occur through
detection of injurious signals including TGF-β, platelet-
derived growth factor (PDGF), IL-13, and connective tissue
growth factor (CTGF). This results in the transdierentiation
of myofibroblasts, with smooth muscle actin, MMP-2 and
MMP-9 expression, and excessive collagen production [20].
Resident fibroblasts can respond to a variety of profibrotic
mediators and dierentiate into myofibroblasts [23]. TGF-
β1 induces transdierentiation of fibroblasts, through a
Smad3-dependent mechanism, to myofibroblasts [24]. In
vivo overexpression of IGFBP-5 induces increased expression
of α-SMA and vimentin in dermal and lung fibroblasts
suggesting fibroblast transdierentiation [25, 26].
Epithelial-myofibroblast transdierentiation from epi-
thelial cells is a specialized version of epithelial-mesen-
chymal transition (EMT), a physiological process in which
epithelial cells can acquire the invasive and motile properties
of mesenchymal cells [27]. Alveolar epithelial cells have been
shown to undergo EMT in vivo during the development
of pulmonary fibrosis [28]. There is also compelling evi-
dence suggesting EMT in alveolar epithelial cells following
exposure to TGF-β both in vitro and in vivo [29–31]. In
addition, circulating bone marrow-derived fibrocytes behave
like mesenchymal stem cells and migrate into sites of lung
injury and become myofibroblasts. These fibrocytes express
type 1 collagen and α-SMA and contribute to lung fibrosis
[32]. It is interesting to note that TGF-β1-induced EMT
is reversed by fibroblast growth factor-1, through ERK
phosphorylation and Smad2 dephosphorylation [33]. This
implies that the therapeutic role of FGF-1 should be defined
in IPF, as inhibiting TGF-β globally may have adverse eects
on its role in tissue homeostasis.
6. Extracellular Matrix and IPF
There is now mounting evidence suggesting that extracellular
matrix (ECM) is involved in both normal physiology as
well as in wide variety of pathophysiological processes.
One possible mechanism of pulmonary fibrosis is the
disruption of ECM which enables cell-to-cell contact of
epithelial cells with fibroblasts, leading to the epithelial cell
induction of fibroblast- and myofibroblast-derived signalling
molecules. The end process of EMT is the degradation
of underlying extracellular matrix with the formation of
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additional mesenchymal cells. Epithelial cell injury causes the
release of a wide variety of growth factors, chemokines and
MMPs, notably MMP-2, MMP-3, and MMP-9, interleukins,
and prostaglandins. Under the influence of these signalling
molecules, epithelial cells, acting together with inflammatory
cells, induce basement membrane disruption and focal
degradation of type IV collagen and laminin [34].
7. Role of TGF-β in IPF
Transforming growth factor beta (TGF-β) is a pleiotropic
regulatory cytokine that is ubiquitously expressed by all
cells and tissues within the body. TGF-β1, of the three
highly homologous mammalian isoforms (TGF-β1-3), is
thought to play a central mediator role in wound healing
and fibrosis [35–37]. There is compelling evidence that TGF-
β1 plays a pivotal role in pathophysiology of IPF. There is
increasing evidence pointing to the profibrogenic eects of
TGF-β both in animal models of IPF and in IPF patients.
Induction of EMT in alveolar epithelial cells following
TGF-β1 overexpression in triple transgenic mice and via
adenoviral-mediated gene transfer induces severe pulmonary
fibrosis. In contrast, ex vivo alveolar epithelial cells cultured
on laminin/collagen mixtures undergo programmed cell
death when exposed to active TGF-β [28].
8. Integrin-Mediated Activation of TGF-β
The integrins are a large family of transmembrane het-
erodimeric cell adhesion receptors which mediate cell-
to-surface interactions either to the extracellular cellular
matrix or to specific cell-surface receptors during cell-cell
interactions [38, 39]. They are composed of α and β dimers
in a noncovalent complex, comprising 24 combinations of
18 α and 8 β subunits. These receptors function as important
regulators that control whole sets of cellular processes includ-
ing cell spreading, retraction, migration, and proliferation.
Integrins contain the specialized binding regions for physical
attachment of cells to the ECM, and through intracellular
domains they form connections to various components of
the actin cytoskeleton and a wide variety of interconnecting
signalling adaptors [40].
The cross talk between integrins and TGF-β signalling is
of considerable interest in a wide variety of physiological and
pathophysiological processes including fibrosis, cancer, and
wound healing. The molecular interactions between TGF-β
and integrins αVβ6 and αVβ8 are of particular interest in the
pathogenetic mechanisms of pulmonary fibrogenesis. The
αVβ6 integrin-dependent activation of TGF-β requires the
binding of the β6 cytoplasmic tail to the actin cytoskeleton
[41]. This activation of TGF-β is highly dependent on the
association of inactive (latent) forms of TGF-β and TGF-
β binding protein-1 (LTBP-1) of the large latent complex
with αVβ6 integrin [42]. Furthermore, lysophosphatidic
acid and stimulation of protease-activated receptor 1 have
shown to activate αVβ6-mediated activation of TGF-β1 via
RhoA and are implicated in the pathogenensis of acute lung
injury and pulmonary fibrosis [43, 44]. Partial inhibition of
αVβ6 integrin-mediated activation of TGF-β1 using small
molecule inhibitors has been shown to possess antifibrotic
activity, without pulmonary inflammation and emphysema
[45].
9. Role of IGFBP-5 in IPF
IGFBP-5 is one of the members of insulin-like growth-
factor-binding protein (IGFBP) family which bind to and
modulate the biological actions of insulin-like growth fac-
tors by interference with receptor binding although these
IGFBPs also have IGF-independent actions [46]. Increased
expression of IGFBP-5 has been described in fibrosis [47,
48]. Increased expression of IGFBP-5 at mRNA and protein
levels was also evident in vitro in primary fibroblasts
cultured from disease-aected skin of patients with systemic
sclerosis/scleroderma, compared with the skin from their
healthy twins. It has been demonstrated that IGFBP-5
induces collagen and fibronectin production from fibroblasts
and induces fibroblast/myofibroblast transdierentiation in
vitro and in vivo [25, 26]. Finally, in vivo overexpression
of IGFBP5, using replication-deficient adenovirus, induced
skin fibrosis in mice which included increased thickness of
the dermis and increased collagen bundle thickness [25] and
induced pulmonary fibrosis with myofibroblastic changes
[26]. Increased expression of α-SMA and vimentin in dermal
fibroblasts was also evident with overexpression of IGFBP-
5. Collectively, these findings suggest that upregulated
expression of IGFBP5 could be an initiating event in ECM
production and indicate its involvement in the development
of fibrosis.
10. Integrin-Dependent Interaction
of IGFBP-5
Integrin αVβ6 expression is constitutively expressed at low
levels in epithelial tissues and was significantly increased dur-
ing injury but was unable to potentiate fibrosis [49]. Recently,
we demonstrated that αVβ6 integrin is also essential in
addition to α2 and β1 integrins for the IGFBP-5-induced
cell to extracellular matrix adhesion in MCF-7 cells. Using
biosensor technology, we showed a novel, direct, high anity
interaction of IGFBP-5 with α2 and β1 integrins leading
to the activation of ILK and Akt and improved epithelial
cell adhesion and survival (our unpublished observations).
Apoptosis of epithelial cells induces IGFBP-5 which activates
tissue plasminogen activator (tPA), generating plasmin, and
also interacts with several matricellular proteins [50]. Thus,
IGFBP-5 may act as a central mediator in the initial response
of epithelial cell injury.
This provides an intriguing possibility in which IGFBP-
5 acts indirectly, extracellularly, in a similar fashion to
connective tissue growth factor (CTGF), which also serves
as a mediator of the actions of TGF-β1 [51]. CTGF is
structurally related to IGFBP-5 and interacts with integrins
to elicit its actions, rather than using classic cell-surface
receptors. In fact, there are similarities between IGFBP-5 and
other members of the secreted cysteine-rich (CCN) protein
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family which includes CTGF, CYR61, and Nov. The CCN
molecules were temporarily renamed IGFBP8-10 because of
their structural relationship with the IGFBP family. However,
we believe that IGFBP-5 may be a member of the CCN family
since it binds and activates integrins, interacts with the ECM
via a heparin-binding domain, and influences growth factor
actions (IGFs) indirectly by binding to them. In analogous
fashion, CTGF as well as binding to integrins and the ECM
binds to VEGF [52] to inhibit its actions and bind to, and
enhances the actions of, TGF-β1 [53].
The adhesive responses to IGFBP-5 could be anticipated
to enhance re-epithelialisation during injury by increasing
the surface area of epithelial cells when epithelia are exposed
to a mesenchymal environment, whilst concurrently inhibit-
ing their migration into the mesenchymal compartment.
Thus, IGFBP-5 would be anticipated to display antagonistic
actions to TGF-β1 in the epithelial compartment whilst
enhancing its actions in the mesenchymal compartment
(Figure 1).
11. TGF-β and IGFBP-5: Redundancy or
Complementarity of Actions?
The recent studies implicating IGFBP-5 in the development
of fibrosis begs the question “Do TGF-β1 and IGFBP-5
serve similar roles and, if so, why? We believe that, although
their roles in the mesenchymal compartment are similar
and certainly complementary, their actions in the epithelial
compartment are dierent. Whereas TGF-β1 is clearly
apoptotic and induces EMT in a proportion of the epithelial
cells, thus disrupting the epithelial compartment and its
functions both as a physical barrier and in, for example,
gas exchange in the lung, the actions of IGFBP-5 are quite
distinct. We have shown that IGFBP-5 induces an adhesive
action [50] in epithelial cells exposed to a mesenchymal envi-
ronment, leading to increased cell spreading and decreased
migration and propose that this serves as a mechanism to
prevent epithelial egress from, and mesenchymal ingress
into, the epithelial compartment. IGFBP-5 also increases
epithelial production of the basement membrane protein,
laminin [54]. These actions would be anticipated to limit
the boundary of the fibrotic response to the underlying
stroma. Thus, IGFBP-5 may be a more relevant target in
therapies of wound repair than TGF-β1, since it enhances
fibrosis but limits scar formation to the mesenchymal
compartment, thereby preventing excessive disruption of the
epithelium. This contrasts with the uncontrolled fibrotic
response characteristically produced by TGF-β1.
12. Clinical Implications
Fibrotic diseases in general, and idiopathic pulmonary
fibrosis in particular, represent disease states for which no
therapies currently exist. Targeting the major fibrotic agents
may provide the prospect of developing such therapies,
and TGF-β1 is, indeed, the target of research programmes
seeking pharmacological inhibitors. The complementary
roles of TGF-β1 and IGFBP-5 in alveolar epithelial cell injury
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Figure 1: Dierential eects of TGF-β1 and IGFBP-5 on mesenchy-
mal and epithelial cells. In fibroblasts, TGF-β1 activates the Smad
pathway resulting in activation of genes associated with fibrosis such
as collagen, fibronectin, and CTGF. CTGF in turn further activates
this process via an aVb3 integrin-dependent mechanism. IGFBP-5
binds to and activates α2β1 integrins and is capable of activating
MAPK pathways in similar fashion to CTGF. In contrast, TGF-β1
activation of the Smad pathway results in an apoptotic pathway
in epithelial cells, whereas IGFBP-5, again acting through α2β1
integrin, stimulates an adhesive, prosurvival pathway. Thus, IGFBP-
5 enhances TGF-β1 actions in the mesenchymal compartment but
inhibits them in the epithelium.
provide additional options for drug targets although a better
understanding of their precise mechanisms of action will be
essential to enhance the prospects of success. Nevertheless,
the potential protective role of IGFBP-5 in the epithelium
is particularly amenable to aerosol-mediated drug delivery
systems, since this would provide direct access to the site
of action required for eective re-epithelialisation to occur.
Possible approaches could include smaller domains of the
IGFBP-5 molecule, which can exert these eects, drugs which
mimic its adhesive, survival eects, or drugs, such as retinoic
acid and vitamin D analogues, that are known to stimulate
its production in epithelial cells [55–57].
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